Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check5 days agoChange DetectedThe site revision label in the footer changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check12 days agoChange DetectedThe footer’s revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now displays a 403 Forbidden error and the Study Documents section has been removed, leaving only the basic header and footer with no downloadable documents.SummaryDifference18%

- Check55 days agoChange DetectedA Funding line '2017 ( U.S. NIH Grant/Contract )' was added to the study details, and the page revision tag was updated from v3.6.5 to v3.6.6.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision tag updated to v3.6.5, replacing the previous v3.6.4. This change reflects a deployment update to the page rather than modification to study data.SummaryDifference0.0%

- Check83 days agoChange DetectedThe Ukraine site entry was updated from Zaporizhzhia to Zaporizhzhya in the locations list, reflecting a transliteration/name update for the city.SummaryDifference0.0%

Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.